Navigation Links
Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., June 20, 2017 /PRNewswire/ --SkylineDx today announced the presentation of new data that validate the use of MMprofiler with SKY92, the company's prognostic tool to risk stratify patients with multiple myeloma (MM). In a poster presentation at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain, SkylineDx researchers will demonstrate the prognostic value of MMprofiler for identifying high-risk elderly patients.

In a separate e-poster presentation at EHA, researchers will present data demonstrating the value of the TOPSPIN (Treatment Outcome Prediction using Similarity between PatIeNts) algorithm in predicting survival in patients with MM who received bortezomib.

"Having already established proof of principle for MMprofiler and the TOPSPIN algorithm, we are gratified to have the utility of these prognostic tools further validated by the data presented at EHA," said Dharminder S. Chahal, Chief Executive Officer of SkylineDx. "We are confident that these datasets will enhance clinicians' understanding of the molecular factors that impact risk stratification and survival in patients with multiple myeloma, and that this knowledge will help improve the management of patients living with this devastating disease."

The following two posters will be presented:

  • Abstract # P677: Rowan Kuiper, SkylineDx
    • Gene Expression Classifier EMC92/SKY92 and Revised ISS Robustly Identify High-Risk Multiple Myeloma in Elderly Patients of the HOVON-87/NMSG-18 Study
    • Poster Presentation: Saturday, June 24, 2017 from 17:30 - 19:00
  • Abstract # E1279: Joske Ubels, SkylineDx and PhD candidate at University Medical Center Utrecht, and Erasmus Medical Center in Rotterdam
    • TOPSPIN: A Novel Algorithm to Predict Treatment Specific Survival in Cancer
    • E-poster presentation

MMprofiler with SKY92 Data
These data validate the SKY92 gene expression classifier as a robust marker for identifying high-risk elderly patients with MM who were enrolled in the HOVON-87/NMSG-18 phase III clinical trial. They compared the SKY92 classifier to the revised International Staging System (R-ISS) for multiple myeloma, a prognostic marker that incorporates the conventional International Staging System with fluorescent in situ hybridization (FISH) to detect chromosomal abnormalities and serum lactate dehydrogenase (LDH). The researchers used MMprofiler to obtain risk scores via the SKY92 signature, which measures the activity of 92 MM-related genes.

A total of 178 patients (median age: 73 years) were analyzed for a median follow up of 34 months. Patients were treated with either melphalan, prednisone and thalidomide (MPT) plus thalidomide maintenance therapy, or melphalan, prednisone, lenalidomide (MPR) plus lenalidomide maintenance. The SKY92 classifier identified 25 patients (14%) as high-risk; the median overall survival (OS) was 21 months for the high-risk patients, compared to 53 months for patients classified as standard-risk (hazard ratio [HR] = 3.0; 95% confidence interval [CI] = 1.7 to 5.3; p < 0.001).

The proportion of patients with stage R-ISS-III MM (indicative of high risk) was 8%, a figure comparable to the 10% in the initial International Myeloma Working Group1 report, which developed the R-ISS. The SKY92 classifier performed better than the R-ISS as a high-risk marker for OS; the two-year OS rate was 48% in the SKY92 high-risk patients, versus 58% for the R-ISS-III patients. In a multivariate analysis, SKY92, R-ISS, and deletion of chromosome 13q were independently associated with OS and progression-free survival (PFS).

"SKY92, revised ISS, and FISH markers such as deletion of 13q retained independent prognostic value," stated lead investigator Rowan Kuiper, Bioinformatician at SkylineDx. "Our data built upon previous findings suggesting that MMprofiler, when used in combination with molecular genetic risk profiling, can enable risk stratification in multiple myeloma by elucidating patterns of survival and disease progression in high-risk patients, and may facilitate evaluation of risk-stratified treatment approaches in this patient population."

TOPSPIN is a new computational algorithm identifying gene sets that predict if a patient is likely to survive longer when receiving a treatment of interest versus alternative treatments. The utility of the TOPSPIN method was demonstrated in a multiple myeloma dataset in which 910 patients either received (n = 407) or did not receive (n = 503) bortezomib therapy. SkylineDx researchers defined gene sets using the Gene Ontology (GO) annotation, which provides functionally related groups of genes; they then tested random gene sets with the same structure as the GO sets.

The researchers report that TOPSPIN successfully identified subsets of patients with longer PFS when treated with bortezomib. They note that 28.4% of patients were classified as "will benefit" (Class 1), resulting in an HR of 0.13 (p =7.1* 10-11) between the two treatment arms. Additionally, in an independent test set an HR of 0.47 (p = 0.03) was observed.

"TOPSPIN combines biological knowledge with high-performance computing, and can be applied to any dataset with two treatment arms and a continuous outcome measure," explained Joske Ubels, Bioinformatician at SkylineDx and PhD candidate at University Medical Center Utrecht, and Erasmus Medical Center in Rotterdam, the Netherlands. "In this study, we used TOPSPIN to identify gene sets that enabled us to predict which patients would benefit from bortezomib. That is an important consideration in a disease such as multiple myeloma, for which there are now many treatments available with a wide range of response rates, making it critical to select the right treatment at the time of diagnosis. With the ability to identify gene sets that inform treatment-specific survival, TOPSPIN enables categorization of patients into two subgroups based on their expected benefit from treatment, thereby facilitating therapeutic decision-making."

About Multiple Myeloma 
Multiple myeloma (MM) is a cancer that arises from plasma cells, a type of white blood cell made in the bone marrow. In patients with MM, the plasma cells become abnormal, multiply uncontrollably, and release only one type of antibody – known as M-protein – which has no useful function. According to the World Cancer Research Fund International, an estimated 114,000 people around the world are diagnosed with MM annually, and the disease represents 0.8% of all cancers globally.

For more information about MM, visit (information available in Dutch only),,,, or

About MMprofiler with SKY92
MMprofiler assesses risk by measuring the activity of 92 MM-related genes that comprise SKY92, the company's novel, prognostic gene classifier. The lead product of SkylineDx, MMprofiler is proven to be superior to the biomarkers currently used to risk-stratify newly diagnosed and relapsed multiple myeloma patients into a "high" or "standard" risk category.2  Included in a growing number of international treatment guidelines, MMprofiler is CE-IVD registered in Europe and will be coming soon as a laboratory-developed test (LDT) in the United States. For more information, please visit   

About SkylineDx
SkylineDx is a commercial-stage biotech company based in Rotterdam, the Netherlands. Originally a spin-off of the Erasmus Medical Center in Rotterdam, the company specializes in the development and marketing of innovative gene signature-based prognostic tests to assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient's response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient. MMprofiler with SKY92 is the company's lead product. To learn more, please visit

1 Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(28):2863-9.
2 Van Beers EH, van Vliet M, de Best L, et al. SKY92 GEP, iFISH, and ISS comparisons for risk stratification in multiple myeloma. Poster p661 presented at 20th European Hematology Association Congress, Vienna, Austria, June 13, 2015.  

To view the original version on PR Newswire, visit:

SOURCE SkylineDx
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
2. CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
3. GenomeDxs Decipher Tests and Decipher GRID to be Featured in Multiple Presentations at the 32nd Annual EAU Congress
4. Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting
5. Spheryx Announces Three Presentations at Pittcon the Worlds Largest Conference for Laboratory Science
6. Regeneron Announces Upcoming 2017 Investor Conference Presentations
7. Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohns and Colitis Organisation - Inflammatory Bowel Diseases 2017
8. Astute Medical Announces NephroCheck Test Presentations At The Society Of Critical Care Medicine Congress
9. GenomeDxs Decipher Prostate and Bladder Data to be Featured in Multiple Presentations at 17th Annual Meeting of the Society of Urologic Oncology
10. Amarantus Announces Upcoming Investor Presentations
11. Lannett Announces Presentations At Upcoming Investor Conferences
Post Your Comments:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):